Exelixis, Inc. or Mesoblast Limited: Who Invests More in Innovation?

Exelixis leads in biotech innovation investment.

__timestampExelixis, Inc.Mesoblast Limited
Wednesday, January 1, 201418910100055305000
Thursday, January 1, 20159635100077593000
Friday, January 1, 20169596700050013000
Sunday, January 1, 201711217100058914000
Monday, January 1, 201818225700065927000
Tuesday, January 1, 201933696400059815000
Wednesday, January 1, 202054785100056188000
Friday, January 1, 202169371600053012000
Saturday, January 1, 202289181300032815000
Sunday, January 1, 2023104407100027189000
Monday, January 1, 202491040800025353000
Loading chart...

In pursuit of knowledge

Innovation Investment: Exelixis, Inc. vs. Mesoblast Limited

In the competitive world of biotechnology, innovation is the key to success. Exelixis, Inc. and Mesoblast Limited are two companies that have consistently invested in research and development (R&D) to drive their growth. Over the past decade, Exelixis has significantly outpaced Mesoblast in R&D spending, with a staggering 1,000% increase from 2014 to 2023. In 2023 alone, Exelixis allocated over 90% more to R&D than Mesoblast, highlighting its commitment to innovation.

Mesoblast, while investing steadily, has seen a more modest increase in R&D expenses, with a peak in 2015. The data suggests that Exelixis's aggressive investment strategy may be positioning it as a leader in the biotech sector. As we look to the future, the question remains: will Mesoblast ramp up its R&D efforts to compete with Exelixis's innovation-driven approach?

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025